Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

THOMAS J GEORGE

Allopathic & Osteopathic Physicians Internal Medicine Hematology & Oncology

NPI
1104867365
CMS profile
321938
Location
GAINESVILLE, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2020 · Entire year

$806.00

2 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2020 · entire year · sorted by reported total

Nature of paymentAmountRecords
Education $806.00 2

By paying entity

PY2020 · entire year · sorted by reported total

Paying entityAmountRecords
E.R. Squibb & Sons, L.L.C. $564.00 1
Celgene Corporation $242.00 1

Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

THOMAS J GEORGE

NPI 1104867365 · CMS profile ID 321938

Allopathic & Osteopathic Physicians / Internal Medicine / Hematology & Oncology

GAINESVILLE, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1104867365?year=2020&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
THOMAS J GEORGE, NPI 1104867365, CMS profile ID 321938. General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1104867365?year=2020&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019.
APA 7
IndustryPayments. (2026). THOMAS J GEORGE, NPI 1104867365, CMS profile ID 321938. General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1104867365?year=2020&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019.
Bluebook
THOMAS J GEORGE, NPI 1104867365, CMS profile ID 321938, IndustryPayments, General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019. https://industrypayments.org/provider/npi-1104867365?year=2020&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2020

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2020 · Physicians and non-physician practitioners · CMS publication 2026-06-30

2 matching records · $806.00 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 2 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–2 of 2.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
E.R. Squibb & Sons, L.L.C. $564.0005/29/2020 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 727814595 CMS
Celgene Corporation $242.0002/11/2020 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 727814587 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $2,139.61 16
PY2020 $806.00 2
PY2021 $5,850.00 2
PY2022 $5,602.52 7
PY2023 $299.42 5
PY2024 $1,820.00 3
PY2025 $2,260.64 3

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $507,584.60 83
PY2024 Recipient $2,598.05 11
PY2024 Principal investigator $596,039.96 28
PY2023 Principal investigator $1,130,234.11 90
PY2022 Principal investigator $1,675,365.46 75
PY2021 Principal investigator $2,129,940.43 124
PY2020 Principal investigator $2,169,106.03 143
PY2019 Principal investigator $2,064,075.98 203

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

124 records in PY2021

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 AstraZeneca Pharmaceuticals LP $328.15 12/31/2021 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
MEDI9447 CD73 Solid Tmr-D6070C00001 Phase 1 Clinical Trial No dispute reported 06/30/2026 826484983
Principal investigator 1 Merck Sharp & Dohme Corporation $3,557.97 12/31/2021 Non-covered Recipient Entity
UF DAVIS CANCER CENTER
A Phase III Study of Pembrolizumab vs Chemotherapy in Microsatellite Instability- High or Mismatched Repair Deficient Colorectal Carcinoma No dispute reported 06/30/2026 848743743
Principal investigator 1 Merck Sharp & Dohme Corporation $123,852.83 12/31/2021 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE
An Open-label, Multicenter, Phase 2 Study to Evaluate the Efficacy and Safety of Pembrolizumab Plus Lenvatinib in Combination With Belzutifan in Multiple Solid Tumors No dispute reported 06/30/2026 848753299
Principal investigator 1 Merck Sharp & Dohme Corporation $38,946.51 12/31/2021 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
A Phase 2 Study of Olaparib in Combination with Pembrolizumab in Participants with Previously Treated, Homologous Recombination Repair Mutation HRRm and,or Homologous Recombination Deficiency HRD Positive Advanced Cancer No dispute reported 06/30/2026 848754525
Principal investigator 1 Merck Sharp & Dohme Corporation $39,096.78 12/31/2021 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
A Phase 2 Study of Olaparib in Combination with Pembrolizumab in Participants with Previously Treated, Homologous Recombination Repair Mutation HRRm and,or Homologous Recombination Deficiency HRD Positive Advanced Cancer No dispute reported 06/30/2026 848754527
Principal investigator 1 Seagen Inc. $20,993.90 12/22/2021 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
Open Label Phase 2 Study of Tisotumab Vedotin for Locally Advanced or Metastatic Disease in Solid Tumors No dispute reported 06/30/2026 792663569
Principal investigator 1 Seagen Inc. $1,300.00 12/22/2021 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
Open Label Phase 2 Study of Tisotumab Vedotin for Locally Advanced or Metastatic Disease in Solid Tumors No dispute reported 06/30/2026 792663573
Principal investigator 1 Ipsen Biopharmaceuticals, Inc $24,720.00 12/06/2021 Non-covered Recipient Entity
University of Florida Board of Trustees
A Phase II, Open-label Pilot Study Evaluating the Safety and Activity of Liposomal Irinotecan in Combination With 5-FU and Oxaliplatin in Preoperative Treatment of Pancreatic Adenocarcinoma (NEO-Nal- IRI Study) No dispute reported 06/30/2026 851706871
Principal investigator 1 Incyte Corporation $18,225.00 12/03/2021 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
A Phase 1b Study of INCMGA00012 in Combination With Other Therapies in Patients With Advanced Solid Tumors No dispute reported 06/30/2026 831135193
Principal investigator 1 Incyte Corporation $650.00 12/03/2021 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
A Phase 1b Study of INCMGA00012 in Combination With Other Therapies in Patients With Advanced Solid Tumors No dispute reported 06/30/2026 831135199
Principal investigator 1 Incyte Corporation $240.00 12/03/2021 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
A Phase 1b Study of INCMGA00012 in Combination With Other Therapies in Patients With Advanced Solid Tumors No dispute reported 06/30/2026 831135205
Principal investigator 1 Incyte Corporation $3,250.00 12/03/2021 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
A Phase 1b Study of INCMGA00012 in Combination With Other Therapies in Patients With Advanced Solid Tumors No dispute reported 06/30/2026 831135211
Principal investigator 1 Incyte Corporation $1,430.00 12/03/2021 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
A Phase 1b Study of INCMGA00012 in Combination With Other Therapies in Patients With Advanced Solid Tumors No dispute reported 06/30/2026 831135217
Principal investigator 1 Incyte Corporation $819.00 12/03/2021 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
A Phase 1b Study of INCMGA00012 in Combination With Other Therapies in Patients With Advanced Solid Tumors No dispute reported 06/30/2026 831135225
Principal investigator 1 Seagen Inc. $682.50 12/02/2021 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
Open Label Phase 2 Study of Tisotumab Vedotin for Locally Advanced or Metastatic Disease in Solid Tumors No dispute reported 06/30/2026 792663585
Principal investigator 1 Ipsen Biopharmaceuticals, Inc $37,080.00 11/19/2021 Non-covered Recipient Entity
University of Florida Board of Trustees
A Phase II, Open-label Pilot Study Evaluating the Safety and Activity of Liposomal Irinotecan in Combination With 5-FU and Oxaliplatin in Preoperative Treatment of Pancreatic Adenocarcinoma (NEO-Nal- IRI Study) No dispute reported 06/30/2026 851706853
Principal investigator 1 Seagen Inc. $4,524.00 11/17/2021 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
Open Label Phase 2 Study of Tisotumab Vedotin for Locally Advanced or Metastatic Disease in Solid Tumors No dispute reported 06/30/2026 792663563
Principal investigator 1 Ipsen Biopharmaceuticals, Inc $59,328.00 11/04/2021 Non-covered Recipient Entity
University of Florida Board of Trustees
A Phase II, Open-label Pilot Study Evaluating the Safety and Activity of Liposomal Irinotecan in Combination With 5-FU and Oxaliplatin in Preoperative Treatment of Pancreatic Adenocarcinoma (NEO-Nal- IRI Study) No dispute reported 06/30/2026 851706859
Principal investigator 1 Incyte Corporation $270.00 10/25/2021 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies No dispute reported 06/30/2026 831135171
Principal investigator 1 Ipsen Biopharmaceuticals, Inc $29,664.00 10/20/2021 Non-covered Recipient Entity
University of Florida Board of Trustees
A Phase II, Open-label Pilot Study Evaluating the Safety and Activity of Liposomal Irinotecan in Combination With 5-FU and Oxaliplatin in Preoperative Treatment of Pancreatic Adenocarcinoma (NEO-Nal- IRI Study) No dispute reported 06/30/2026 851706865
Principal investigator 1 Ipsen Biopharmaceuticals, Inc $27,192.00 10/19/2021 Non-covered Recipient Entity
University of Florida Board of Trustees
A Phase II, Open-label Pilot Study Evaluating the Safety and Activity of Liposomal Irinotecan in Combination With 5-FU and Oxaliplatin in Preoperative Treatment of Pancreatic Adenocarcinoma (NEO-Nal- IRI Study) No dispute reported 06/30/2026 851706847
Principal investigator 1 Merck Sharp & Dohme Corporation $22,166.14 10/15/2021 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
A Phase 2 Study of Olaparib in Combination with Pembrolizumab in Participants with Previously Treated, Homologous Recombination Repair Mutation HRRm and,or Homologous Recombination Deficiency HRD Positive Advanced Cancer No dispute reported 06/30/2026 848754523
Principal investigator 1 GlaxoSmithKline, LLC. $118,137.90 10/06/2021 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA DIVISION OF HEMATOLOGY & ONCOLOGY
0000000000000000000000000000000000000000000000000000000000000000214456 No dispute reported 06/30/2026 965538747
Principal investigator 1 Seagen Inc. $1,560.00 10/06/2021 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
Open Label Phase 2 Study of Tisotumab Vedotin for Locally Advanced or Metastatic Disease in Solid Tumors No dispute reported 06/30/2026 792663557
Principal investigator 1 Seagen Inc. $455.00 10/06/2021 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
Open Label Phase 2 Study of Tisotumab Vedotin for Locally Advanced or Metastatic Disease in Solid Tumors No dispute reported 06/30/2026 792663579
Principal investigator 1 TerSera Therapeutics LLC $1,848.60 10/01/2021 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA (416)
A Phase 2, Multicenter, open-label, safety and efficacy study of Xermelo (telotristat ethyl) plus first-line chemotherapy in patients with locally advanced, unresectable, recurrent or metastatic biliary tract cancer No dispute reported 06/30/2026 845547715
Principal investigator 1 Incyte Corporation $597.60 09/29/2021 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
A Phase 1b Study of INCMGA00012 in Combination With Other Therapies in Patients With Advanced Solid Tumors No dispute reported 06/30/2026 831135041
Principal investigator 1 Genentech, Inc. $1,540.50 09/27/2021 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
TUMOR AGNOSTIC PRECISION IMMUNO ONCOLOGY AND SOMATIC TARGETING RATIONAL FOR YOU TAPISTRY PHASE II No dispute reported 06/30/2026 836038587
Principal investigator 1 Seagen Inc. $32,406.96 09/22/2021 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
Open Label Phase 2 Study of Tisotumab Vedotin for Locally Advanced or Metastatic Disease in Solid Tumors No dispute reported 06/30/2026 792663495
Principal investigator 1 Incyte Corporation $23.40 09/09/2021 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
A Phase 1-2 Study of Combination Therapy With INCMGA00012 (Anti-PD-1), INCAGN02385 (Anti-LAG-3), and INCAGN02390 (Anti-TIM-3) in Participants With Select Advanced Malignancies No dispute reported 06/30/2026 831135047
Principal investigator 1 Incyte Corporation $20.26 09/09/2021 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
A Phase 1-2 Study of Combination Therapy With INCMGA00012 (Anti-PD-1), INCAGN02385 (Anti-LAG-3), and INCAGN02390 (Anti-TIM-3) in Participants With Select Advanced Malignancies No dispute reported 06/30/2026 831135053
Principal investigator 1 Incyte Corporation $1.36 09/09/2021 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
A Phase 1-2 Study of Combination Therapy With INCMGA00012 (Anti-PD-1), INCAGN02385 (Anti-LAG-3), and INCAGN02390 (Anti-TIM-3) in Participants With Select Advanced Malignancies No dispute reported 06/30/2026 831135059
Principal investigator 1 Incyte Corporation $42.36 09/09/2021 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
A Phase 1-2 Study of Combination Therapy With INCMGA00012 (Anti-PD-1), INCAGN02385 (Anti-LAG-3), and INCAGN02390 (Anti-TIM-3) in Participants With Select Advanced Malignancies No dispute reported 06/30/2026 831135065
Principal investigator 1 Incyte Corporation $2.16 09/09/2021 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
A Phase 1-2 Study of Combination Therapy With INCMGA00012 (Anti-PD-1), INCAGN02385 (Anti-LAG-3), and INCAGN02390 (Anti-TIM-3) in Participants With Select Advanced Malignancies No dispute reported 06/30/2026 831135071
Principal investigator 1 Incyte Corporation $24.08 09/09/2021 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
A Phase 1-2 Study of Combination Therapy With INCMGA00012 (Anti-PD-1), INCAGN02385 (Anti-LAG-3), and INCAGN02390 (Anti-TIM-3) in Participants With Select Advanced Malignancies No dispute reported 06/30/2026 831135077
Principal investigator 1 Incyte Corporation $2.31 09/09/2021 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
A Phase 1-2 Study of Combination Therapy With INCMGA00012 (Anti-PD-1), INCAGN02385 (Anti-LAG-3), and INCAGN02390 (Anti-TIM-3) in Participants With Select Advanced Malignancies No dispute reported 06/30/2026 831135083
Principal investigator 1 Incyte Corporation $48.72 09/09/2021 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
A Phase 1-2 Study of Combination Therapy With INCMGA00012 (Anti-PD-1), INCAGN02385 (Anti-LAG-3), and INCAGN02390 (Anti-TIM-3) in Participants With Select Advanced Malignancies No dispute reported 06/30/2026 831135089
Principal investigator 1 Incyte Corporation $23.40 09/09/2021 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
A Phase 1-2 Study of Combination Therapy With INCMGA00012 (Anti-PD-1), INCAGN02385 (Anti-LAG-3), and INCAGN02390 (Anti-TIM-3) in Participants With Select Advanced Malignancies No dispute reported 06/30/2026 831135093
Principal investigator 1 Incyte Corporation $23.40 09/09/2021 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
A Phase 1-2 Study of Combination Therapy With INCMGA00012 (Anti-PD-1), INCAGN02385 (Anti-LAG-3), and INCAGN02390 (Anti-TIM-3) in Participants With Select Advanced Malignancies No dispute reported 06/30/2026 831135099
Principal investigator 1 Incyte Corporation $23.40 09/09/2021 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
A Phase 1-2 Study of Combination Therapy With INCMGA00012 (Anti-PD-1), INCAGN02385 (Anti-LAG-3), and INCAGN02390 (Anti-TIM-3) in Participants With Select Advanced Malignancies No dispute reported 06/30/2026 831135105
Principal investigator 1 Incyte Corporation $23.40 09/09/2021 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
A Phase 1-2 Study of Combination Therapy With INCMGA00012 (Anti-PD-1), INCAGN02385 (Anti-LAG-3), and INCAGN02390 (Anti-TIM-3) in Participants With Select Advanced Malignancies No dispute reported 06/30/2026 831135111
Principal investigator 1 Incyte Corporation $23.40 09/09/2021 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
A Phase 1-2 Study of Combination Therapy With INCMGA00012 (Anti-PD-1), INCAGN02385 (Anti-LAG-3), and INCAGN02390 (Anti-TIM-3) in Participants With Select Advanced Malignancies No dispute reported 06/30/2026 831135117
Principal investigator 1 Incyte Corporation $1.36 09/09/2021 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
A Phase 1-2 Study of Combination Therapy With INCMGA00012 (Anti-PD-1), INCAGN02385 (Anti-LAG-3), and INCAGN02390 (Anti-TIM-3) in Participants With Select Advanced Malignancies No dispute reported 06/30/2026 831135123
Principal investigator 1 Incyte Corporation $42.36 09/09/2021 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
A Phase 1-2 Study of Combination Therapy With INCMGA00012 (Anti-PD-1), INCAGN02385 (Anti-LAG-3), and INCAGN02390 (Anti-TIM-3) in Participants With Select Advanced Malignancies No dispute reported 06/30/2026 831135129
Principal investigator 1 Incyte Corporation $2.16 09/09/2021 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
A Phase 1-2 Study of Combination Therapy With INCMGA00012 (Anti-PD-1), INCAGN02385 (Anti-LAG-3), and INCAGN02390 (Anti-TIM-3) in Participants With Select Advanced Malignancies No dispute reported 06/30/2026 831135135
Principal investigator 1 Incyte Corporation $24.08 09/09/2021 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
A Phase 1-2 Study of Combination Therapy With INCMGA00012 (Anti-PD-1), INCAGN02385 (Anti-LAG-3), and INCAGN02390 (Anti-TIM-3) in Participants With Select Advanced Malignancies No dispute reported 06/30/2026 831135141
Principal investigator 1 Incyte Corporation $2.31 09/09/2021 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
A Phase 1-2 Study of Combination Therapy With INCMGA00012 (Anti-PD-1), INCAGN02385 (Anti-LAG-3), and INCAGN02390 (Anti-TIM-3) in Participants With Select Advanced Malignancies No dispute reported 06/30/2026 831135147
Principal investigator 1 Incyte Corporation $48.72 09/09/2021 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
A Phase 1-2 Study of Combination Therapy With INCMGA00012 (Anti-PD-1), INCAGN02385 (Anti-LAG-3), and INCAGN02390 (Anti-TIM-3) in Participants With Select Advanced Malignancies No dispute reported 06/30/2026 831135153
Principal investigator 1 Incyte Corporation $48.72 09/09/2021 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
A Phase 1-2 Study of Combination Therapy With INCMGA00012 (Anti-PD-1), INCAGN02385 (Anti-LAG-3), and INCAGN02390 (Anti-TIM-3) in Participants With Select Advanced Malignancies No dispute reported 06/30/2026 831135159
Principal investigator 1 Incyte Corporation $48.72 09/09/2021 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
A Phase 1-2 Study of Combination Therapy With INCMGA00012 (Anti-PD-1), INCAGN02385 (Anti-LAG-3), and INCAGN02390 (Anti-TIM-3) in Participants With Select Advanced Malignancies No dispute reported 06/30/2026 831135165
Principal investigator 1 Ipsen Biopharmaceuticals, Inc $29,664.00 09/08/2021 Non-covered Recipient Entity
University of Florida Board of Trustees
A Phase II, Open-label Pilot Study Evaluating the Safety and Activity of Liposomal Irinotecan in Combination With 5-FU and Oxaliplatin in Preoperative Treatment of Pancreatic Adenocarcinoma (NEO-Nal- IRI Study) No dispute reported 06/30/2026 851706583
Principal investigator 1 Incyte Corporation $15,063.00 08/25/2021 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies No dispute reported 06/30/2026 831135007
Principal investigator 1 Incyte Corporation $12,166.00 08/25/2021 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies No dispute reported 06/30/2026 831135013
Principal investigator 1 Incyte Corporation $10,906.00 08/25/2021 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies No dispute reported 06/30/2026 831135017
Principal investigator 1 Incyte Corporation $2,880.00 08/25/2021 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies No dispute reported 06/30/2026 831135023
Principal investigator 1 Incyte Corporation $6,048.00 08/25/2021 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies No dispute reported 06/30/2026 831135029
Principal investigator 1 Incyte Corporation $4,224.00 08/20/2021 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies No dispute reported 06/30/2026 831135001
Principal investigator 1 Incyte Corporation $512.00 08/20/2021 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies No dispute reported 06/30/2026 831135035
Principal investigator 1 GlaxoSmithKline, LLC. $118,137.90 08/19/2021 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA DIVISION OF HEMATOLOGY & ONCOLOGY
0000000000000000000000000000000000000000000000000000000000000000214456 No dispute reported 06/30/2026 965538739
Principal investigator 1 Ipsen Biopharmaceuticals, Inc $24,720.00 08/19/2021 Non-covered Recipient Entity
University of Florida Board of Trustees
A Phase II, Open-label Pilot Study Evaluating the Safety and Activity of Liposomal Irinotecan in Combination With 5-FU and Oxaliplatin in Preoperative Treatment of Pancreatic Adenocarcinoma (NEO-Nal- IRI Study) No dispute reported 06/30/2026 851706577
Principal investigator 1 GlaxoSmithKline, LLC. $165,393.06 08/18/2021 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA DIVISION OF HEMATOLOGY & ONCOLOGY
0000000000000000000000000000000000000000000000000000000000000000214456 No dispute reported 06/30/2026 965538791
Principal investigator 1 Seagen Inc. $227.50 08/11/2021 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
Open Label Phase 2 Study of Tisotumab Vedotin for Locally Advanced or Metastatic Disease in Solid Tumors No dispute reported 06/30/2026 792663499
Principal investigator 1 GlaxoSmithKline, LLC. $118,137.90 07/28/2021 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA DIVISION OF HEMATOLOGY & ONCOLOGY
0000000000000000000000000000000000000000000000000000000000000000214456 No dispute reported 06/30/2026 965538743
Principal investigator 1 GlaxoSmithKline, LLC. $165,393.06 07/27/2021 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA DIVISION OF HEMATOLOGY & ONCOLOGY
0000000000000000000000000000000000000000000000000000000000000000214456 No dispute reported 06/30/2026 965538789
Principal investigator 1 GlaxoSmithKline, LLC. $94,510.32 07/14/2021 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA DIVISION OF HEMATOLOGY & ONCOLOGY
0000000000000000000000000000000000000000000000000000000000000000214456 No dispute reported 06/30/2026 965538793
Principal investigator 1 Ipsen Biopharmaceuticals, Inc $51,912.00 07/14/2021 Non-covered Recipient Entity
University of Florida Board of Trustees
A Phase II, Open-label Pilot Study Evaluating the Safety and Activity of Liposomal Irinotecan in Combination With 5-FU and Oxaliplatin in Preoperative Treatment of Pancreatic Adenocarcinoma (NEO-Nal- IRI Study) No dispute reported 06/30/2026 851706571
Principal investigator 1 AstraZeneca Pharmaceuticals LP $5,274.24 07/09/2021 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
MEDI9447 CD73 Solid Tmr-D6070C00001 Phase 1 Clinical Trial No dispute reported 06/30/2026 826480361
Principal investigator 1 Merck Sharp & Dohme Corporation $200.00 06/25/2021 Non-covered Recipient Entity
UF DAVIS CANCER CENTER
A Phase III Study of Pembrolizumab vs Chemotherapy in Microsatellite Instability- High or Mismatched Repair Deficient Colorectal Carcinoma No dispute reported 06/30/2026 848743741
Principal investigator 1 TerSera Therapeutics LLC $15,128.10 06/22/2021 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA (416)
A Phase 2, Multicenter, open-label, safety and efficacy study of Xermelo (telotristat ethyl) plus first-line chemotherapy in patients with locally advanced, unresectable, recurrent or metastatic biliary tract cancer No dispute reported 06/30/2026 845547713
Principal investigator 1 Seagen Inc. $5,265.00 06/16/2021 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
Open Label Phase 2 Study of Tisotumab Vedotin for Locally Advanced or Metastatic Disease in Solid Tumors No dispute reported 06/30/2026 792663399
Principal investigator 1 Seagen Inc. $1,185.60 06/16/2021 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
Open Label Phase 2 Study of Tisotumab Vedotin for Locally Advanced or Metastatic Disease in Solid Tumors No dispute reported 06/30/2026 792663409
Principal investigator 1 Seagen Inc. $260.00 06/09/2021 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
Open Label Phase 2 Study of Tisotumab Vedotin for Locally Advanced or Metastatic Disease in Solid Tumors No dispute reported 06/30/2026 792663393
Principal investigator 1 Ipsen Biopharmaceuticals, Inc $29,664.00 06/01/2021 Non-covered Recipient Entity
University of Florida Board of Trustees
Safety & activity of Onivyde with 5-FU & Oxaliplatin in borderline resectable pancreatic adenocarcinoma No dispute reported 06/30/2026 851706357
Principal investigator 1 Ipsen Biopharmaceuticals, Inc $20,676.00 05/28/2021 Non-covered Recipient Entity
University of Florida Board of Trustees
Safety & activity of Onivyde with 5-FU & Oxaliplatin in borderline resectable pancreatic adenocarcinoma No dispute reported 06/30/2026 851706329
Principal investigator 1 Ipsen Biopharmaceuticals, Inc $24,720.00 05/21/2021 Non-covered Recipient Entity
University of Florida Board of Trustees
Safety & activity of Onivyde with 5-FU & Oxaliplatin in borderline resectable pancreatic adenocarcinoma No dispute reported 06/30/2026 851706341
Principal investigator 1 Ipsen Biopharmaceuticals, Inc $14,832.00 05/17/2021 Non-covered Recipient Entity
University of Florida Board of Trustees
Safety & activity of Onivyde with 5-FU & Oxaliplatin in borderline resectable pancreatic adenocarcinoma No dispute reported 06/30/2026 851706353
Principal investigator 1 Seagen Inc. $975.00 05/12/2021 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
Open Label Phase 2 Study of Tisotumab Vedotin for Locally Advanced or Metastatic Disease in Solid Tumors No dispute reported 06/30/2026 792663387
Principal investigator 1 Genentech, Inc. $24,375.00 05/03/2021 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
TUMOR AGNOSTIC PRECISION IMMUNO ONCOLOGY AND SOMATIC TARGETING RATIONAL FOR YOU TAPISTRY PHASE II No dispute reported 06/30/2026 836038591
Principal investigator 1 Incyte Corporation $147.00 04/30/2021 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies No dispute reported 06/30/2026 831134913
Principal investigator 1 TerSera Therapeutics LLC $2,445.30 04/27/2021 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA (416)
A Phase 2, Multicenter, open-label, safety and efficacy study of Xermelo (telotristat ethyl) plus first-line chemotherapy in patients with locally advanced, unresectable, recurrent or metastatic biliary tract cancer No dispute reported 06/30/2026 845547711
Principal investigator 1 GlaxoSmithKline, LLC. $24,828.76 04/22/2021 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
A PHASE II TRIAL OF THE PARP INHIBITOR, NIRAPARIB, IN BAP1 AND OTHER D No dispute reported 06/30/2026 809481213
Principal investigator 1 Ipsen Biopharmaceuticals, Inc $74,160.00 04/21/2021 Non-covered Recipient Entity
University of Florida Board of Trustees
Safety & activity of Onivyde with 5-FU & Oxaliplatin in borderline resectable pancreatic adenocarcinoma No dispute reported 06/30/2026 851706335
Principal investigator 1 Ipsen Biopharmaceuticals, Inc $14,832.00 04/16/2021 Non-covered Recipient Entity
University of Florida Board of Trustees
Safety & activity of Onivyde with 5-FU & Oxaliplatin in borderline resectable pancreatic adenocarcinoma No dispute reported 06/30/2026 851706347
Principal investigator 1 Seagen Inc. $873.52 04/14/2021 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
Open Label Phase 2 Study of Tisotumab Vedotin for Locally Advanced or Metastatic Disease in Solid Tumors No dispute reported 06/30/2026 792663383
Principal investigator 1 GlaxoSmithKline, LLC. $141,765.48 04/09/2021 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA DIVISION OF HEMATOLOGY & ONCOLOGY
0000000000000000000000000000000000000000000000000000000000000000214456 No dispute reported 06/30/2026 965538745
Principal investigator 1 Seagen Inc. $256.10 04/07/2021 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
Open Label Phase 2 Study of Tisotumab Vedotin for Locally Advanced or Metastatic Disease in Solid Tumors No dispute reported 06/30/2026 792663371
Principal investigator 1 Seagen Inc. $260.00 04/07/2021 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
Open Label Phase 2 Study of Tisotumab Vedotin for Locally Advanced or Metastatic Disease in Solid Tumors No dispute reported 06/30/2026 792663377
Principal investigator 1 Seagen Inc. $2,601.30 04/07/2021 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
Open Label Phase 2 Study of Tisotumab Vedotin for Locally Advanced or Metastatic Disease in Solid Tumors No dispute reported 06/30/2026 792663403
Principal investigator 1 Incyte Corporation $1,202.50 04/01/2021 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
A Phase 2, Open Label, Single Arm, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Including FGFR2 Translocations Who Failed Previous Therapy No dispute reported 06/30/2026 831134959
Principal investigator 1 Incyte Corporation $546.00 03/31/2021 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
A Phase 1b Study of INCMGA00012 in Combination With Other Therapies in Patients With Advanced Solid Tumors No dispute reported 06/30/2026 831134801
Principal investigator 1 Incyte Corporation $4,641.00 03/31/2021 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
A Phase 1b Study of INCMGA00012 in Combination With Other Therapies in Patients With Advanced Solid Tumors No dispute reported 06/30/2026 831134807
Principal investigator 1 Incyte Corporation $1,300.00 03/31/2021 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
A Phase 1b Study of INCMGA00012 in Combination With Other Therapies in Patients With Advanced Solid Tumors No dispute reported 06/30/2026 831134813
Principal investigator 1 Incyte Corporation $1,165.00 03/31/2021 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
A Phase 1b Study of INCMGA00012 in Combination With Other Therapies in Patients With Advanced Solid Tumors No dispute reported 06/30/2026 831134819
Principal investigator 1 Incyte Corporation $294.00 03/31/2021 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies No dispute reported 06/30/2026 831134823
Principal investigator 1 Incyte Corporation $8,451.90 03/10/2021 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
A Phase 1b Study of INCMGA00012 in Combination With Other Therapies in Patients With Advanced Solid Tumors No dispute reported 06/30/2026 831134795
Principal investigator 1 Seagen Inc. $5,434.00 03/03/2021 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
Open Label Phase 2 Study of Tisotumab Vedotin for Locally Advanced or Metastatic Disease in Solid Tumors No dispute reported 06/30/2026 792663323
Principal investigator 1 Seagen Inc. $85.66 03/03/2021 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
Open Label Phase 2 Study of Tisotumab Vedotin for Locally Advanced or Metastatic Disease in Solid Tumors No dispute reported 06/30/2026 792663328
Principal investigator 1 Eli Lilly and Company $5,690.00 03/01/2021 Non-covered Recipient Entity
WASHINGTON UNIVERSITY
RANDOMIZED, DOUBLE-BLIND, PHASE 2 STUDY OF RAMUCIRUMAB OR MERESTINIB OR PLACEBO PLUS CISPLATIN AND GEMCITABINE AS FIRST-LINE TREATMENT IN PATIENTS WITH ADVANCED OR METASTATIC BILIARY TRACT CANCER No dispute reported 06/30/2026 819469753
Principal investigator 1 Seagen Inc. $26,216.66 02/10/2021 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
Open Label Phase 2 Study of Tisotumab Vedotin for Locally Advanced or Metastatic Disease in Solid Tumors No dispute reported 06/30/2026 792663307
Principal investigator 1 Incyte Corporation $4,642.20 02/04/2021 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
A Phase 1b Study of INCMGA00012 in Combination With Other Therapies in Patients With Advanced Solid Tumors No dispute reported 06/30/2026 831134789
Principal investigator 1 Seagen Inc. $520.00 02/03/2021 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
Open Label Phase 2 Study of Tisotumab Vedotin for Locally Advanced or Metastatic Disease in Solid Tumors No dispute reported 06/30/2026 792663295
Principal investigator 1 Seagen Inc. $2,607.52 02/03/2021 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
Open Label Phase 2 Study of Tisotumab Vedotin for Locally Advanced or Metastatic Disease in Solid Tumors No dispute reported 06/30/2026 792663301
Principal investigator 1 Seagen Inc. $1,862.14 02/03/2021 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
Open Label Phase 2 Study of Tisotumab Vedotin for Locally Advanced or Metastatic Disease in Solid Tumors No dispute reported 06/30/2026 792663313
Principal investigator 1 Seagen Inc. $260.00 02/03/2021 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
Open Label Phase 2 Study of Tisotumab Vedotin for Locally Advanced or Metastatic Disease in Solid Tumors No dispute reported 06/30/2026 792663317
Principal investigator 1 Seagen Inc. $18,036.20 02/03/2021 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
Open Label Phase 2 Study of Tisotumab Vedotin for Locally Advanced or Metastatic Disease in Solid Tumors No dispute reported 06/30/2026 792663333
Principal investigator 1 Incyte Corporation $735.00 01/29/2021 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies No dispute reported 06/30/2026 831134783
Principal investigator 1 Amgen Inc. $59,678.00 01/20/2021 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA HEALTH
AMG 510_P1/2 Monotherapy NSCLC/CRC/Tumor Agnostic_20170543 No dispute reported 06/30/2026 830979511
Principal investigator 1 AstraZeneca Pharmaceuticals LP $3,350.00 01/20/2021 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA HEALTH WOMENS HEALTH SPECIALISTS
A Phase II Study to Assess the Activity of PD-L1 Inhibition with Durvalumab after Chemo-Radiotherapy in Patients with Stage II-IV Microsatelite Stable (MSS) Rectal Cancer No dispute reported 06/30/2026 826461489
Principal investigator 1 GlaxoSmithKline, LLC. $94,510.32 01/13/2021 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA DIVISION OF HEMATOLOGY & ONCOLOGY
0000000000000000000000000000000000000000000000000000000000000000214456 No dispute reported 06/30/2026 965538741
Principal investigator 1 Incyte Corporation $94.00 01/11/2021 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
A Phase 1b Study of INCMGA00012 in Combination With Other Therapies in Patients With Advanced Solid Tumors No dispute reported 06/30/2026 831134829
Principal investigator 1 Incyte Corporation $38.20 01/11/2021 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
A Phase 1b Study of INCMGA00012 in Combination With Other Therapies in Patients With Advanced Solid Tumors No dispute reported 06/30/2026 831134835
Principal investigator 1 Incyte Corporation $19.10 01/11/2021 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
A Phase 1b Study of INCMGA00012 in Combination With Other Therapies in Patients With Advanced Solid Tumors No dispute reported 06/30/2026 831134841
Principal investigator 1 Incyte Corporation $60.80 01/11/2021 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
A Phase 1b Study of INCMGA00012 in Combination With Other Therapies in Patients With Advanced Solid Tumors No dispute reported 06/30/2026 831134849
Principal investigator 1 Incyte Corporation $23.40 01/11/2021 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
A Phase 1b Study of INCMGA00012 in Combination With Other Therapies in Patients With Advanced Solid Tumors No dispute reported 06/30/2026 831134855
Principal investigator 1 Incyte Corporation $30.40 01/11/2021 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
A Phase 1b Study of INCMGA00012 in Combination With Other Therapies in Patients With Advanced Solid Tumors No dispute reported 06/30/2026 831134861
Principal investigator 1 Incyte Corporation $46.80 01/11/2021 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
A Phase 1b Study of INCMGA00012 in Combination With Other Therapies in Patients With Advanced Solid Tumors No dispute reported 06/30/2026 831134867
Principal investigator 1 Incyte Corporation $80.20 01/11/2021 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
A Phase 1b Study of INCMGA00012 in Combination With Other Therapies in Patients With Advanced Solid Tumors No dispute reported 06/30/2026 831134871
Principal investigator 1 Incyte Corporation $19.10 01/11/2021 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
A Phase 1b Study of INCMGA00012 in Combination With Other Therapies in Patients With Advanced Solid Tumors No dispute reported 06/30/2026 831134883
Principal investigator 1 Incyte Corporation $19.10 01/11/2021 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
A Phase 1b Study of INCMGA00012 in Combination With Other Therapies in Patients With Advanced Solid Tumors No dispute reported 06/30/2026 831134889
Principal investigator 1 Incyte Corporation $19.10 01/11/2021 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
A Phase 1b Study of INCMGA00012 in Combination With Other Therapies in Patients With Advanced Solid Tumors No dispute reported 06/30/2026 831134895
Principal investigator 1 Incyte Corporation $23.40 01/11/2021 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
A Phase 1b Study of INCMGA00012 in Combination With Other Therapies in Patients With Advanced Solid Tumors No dispute reported 06/30/2026 831134901
Principal investigator 1 Incyte Corporation $38.20 01/11/2021 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA
A Phase 1b Study of INCMGA00012 in Combination With Other Therapies in Patients With Advanced Solid Tumors No dispute reported 06/30/2026 831134907
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $23,528.00 01/07/2021 Non-covered Recipient Entity
University Of Florida Board Of Trustees
A Study to Test Combination Treatments in Patients With Advanced Gastric Cancer No dispute reported 06/30/2026 819904111
Principal investigator 1 Amgen Inc. $24,689.97 01/05/2021 Non-covered Recipient Entity
UNIVERSITY OF FLORIDA HEALTH
AMG 510_P1/2 Monotherapy NSCLC/CRC/Tumor Agnostic_20170543 No dispute reported 06/30/2026 830979513